Launches VoteAnavex.com to Provide Additional Information on Anavex’s Director Nominees and How to Vote at the Annual Meeting of Stockholders NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE)...
Files Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote "FOR" All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan...
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences Mr. Patel and Dr. Senderowicz to Stand for Election at...
Anavex Life Sciences: Fiscal Q2 Earnings Snapshot
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental...
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative...
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the objective...